Success Metrics

Clinical Success Rate
84.8%

Based on 67 completed trials

Completion Rate
85%(67/79)
Active Trials
5(5%)
Results Posted
49%(33 trials)
Terminated
12(13%)

Phase Distribution

Ph phase_4
40
42%
Ph phase_1
6
6%
Ph early_phase_1
1
1%
Ph not_applicable
7
7%
Ph phase_3
23
24%
Ph phase_2
17
18%

Phase Distribution

7

Early Stage

17

Mid Stage

63

Late Stage

Phase Distribution94 total trials
Early Phase 1First-in-human
1(1.1%)
Phase 1Safety & dosage
6(6.4%)
Phase 2Efficacy & side effects
17(18.1%)
Phase 3Large-scale testing
23(24.5%)
Phase 4Post-market surveillance
40(42.6%)
N/ANon-phased studies
7(7.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.8%

67 of 80 finished

Non-Completion Rate

16.3%

13 ended early

Currently Active

5

trials recruiting

Total Trials

96

all time

Status Distribution
Active(7)
Completed(67)
Terminated(13)
Other(9)

Detailed Status

Completed67
Terminated12
unknown9
Recruiting5
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
96
Active
5
Success Rate
84.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.1%)
Phase 16 (6.4%)
Phase 217 (18.1%)
Phase 323 (24.5%)
Phase 440 (42.6%)
N/A7 (7.4%)

Trials by Status

not_yet_recruiting22%
recruiting55%
withdrawn11%
unknown99%
terminated1213%
completed6770%

Recent Activity

Clinical Trials (96)

Showing 20 of 96 trialsScroll for more
NCT03475186Phase 2

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Completed
NCT01037530Phase 4

Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants

Completed
NCT07259512Phase 4

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

Recruiting
NCT03440177

Bariatric Surgery and Pharmacokinetics of Ramipril

Recruiting
NCT02842424Phase 4

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

Recruiting
NCT02901977Phase 4

Doxazosin and Ramipril in Hypertension

Completed
NCT00933231Phase 3

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Completed
NCT05508035Phase 3

The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction

Recruiting
NCT02008786Phase 4

Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

Terminated
NCT06304896Phase 1

Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy

Not Yet Recruiting
NCT00274599Phase 4

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Completed
NCT04354350

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Completed
NCT02924727Phase 3

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Completed
NCT03715998Phase 2

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Completed
NCT03414723Phase 1

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Completed
NCT02236806Phase 3

Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Unknown
NCT05133050Not Applicable

Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

Not Yet Recruiting
NCT02499822Phase 4

REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial

Completed
NCT03201185Phase 4

Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)

Unknown
NCT04582097Phase 2

Ramipril in Pediatric Patients on Hemodialysis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
96